2 studies found for:    23306000 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
Conditions: HIV;   Acute HIV Infection
Intervention: Drug: DTG/3TC/ABC FDC
2 Active, not recruiting
Has Results
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572 (dolutegravir);   Drug: raltegravir;   Other: GSK1349572 Placebo;   Other: ABC/3TC;   Other: TDF/FTC;   Other: raltegravir Placebo

Indicates status has not been verified in more than two years